A new study by the National Bureau of Economic Research (NBER) finds that middle-aged Americans taking GLP-1 drugs for obesity save an average of $192,735 in lifetime medical costs. The savings are even higher, at $220,000, for adults aged 40 to 50 without college degrees. This research highlights the financial impact of GLP-1s amid their growing use by over 40 million Americans for weight loss, according to fortune.com.
The study’s lead author, Felipe Montano-Campos, explained that obesity is a major comorbidity for many chronic conditions, so treating it with GLP-1s reduces related medical expenses. Unlike traditional weight-loss methods that rely on diet and exercise, GLP-1s provide a pharmacological approach that benefits all users, especially those with lower educational attainment. Montano-Campos noted that these individuals see the greatest financial benefit from the treatment, as reported by fortune.com.
The findings come as GLP-1 drugs have driven billions in revenue for pharmaceutical companies like Eli Lilly and Novo Nordisk, fueled by social media and celebrity endorsements. The market for these drugs could reach $240 billion, reshaping healthcare and consumer behavior. This study underscores the broader economic effects of GLP-1s beyond pharma profits, revealing substantial cost savings in medical care for obesity-related conditions, per fortune.com.
The NBER report specifically quantifies the lifetime medical cost savings for 40- to 50-year-olds using GLP-1s, with the highest benefits among those without college degrees. This data provides a concrete measure of the drugs’ impact on healthcare spending, as detailed on fortune.com.